GMAB
Genmab
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: GMAB
- PE Ratio
As of Jun 5, 2026, the Genmab stock's PE ratio is 18.91. This takes into account the latest EPS of $1.33 and stock price of $25.15. The PE ratio marks an increase of 19% from its last 4 quarters average of 15.8.
GMAB PE ratio history
The PE ratio of Genmab has averaged 38.53 over the last nine years. The current P/E ratio of 18.91 is 51% lower than the historical average. Looking back at the last nine years, GMAB's PE ratio peaked in the Jun 2021 quarter at 75.61, when the price was $40.83 and the EPS was $0.54. The lowest point was in the Jun 2025 quarter, when it reached 10.28 with a price of $20.66 and an EPS of $2.01.
Genmab PE ratio by year
Maximum annual increase: 68.53% in 2025
Maximum annual decrease: -64.08% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 19.87 | 68.53% | $30.8 | $1.55 |
| 2024 | 11.79 | -64.08% | $20.87 | $1.77 |
| 2023 | 32.82 | -10.94% | $31.84 | $0.97 |
| 2022 | 36.85 | -41.31% | $42.38 | $1.15 |
| 2021 | 62.79 | 57.53% | $39.56 | $0.63 |
| 2020 | 39.86 | -14.32% | $40.66 | $1.02 |
| 2019 | 46.52 | -4.16% | $22.33 | $0.48 |
| 2018 | 48.54 | -26.79% | $16.5 | $0.34 |
| 2017 | 66.3 | N/A | $16.58 | $0.25 |
Genmab PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 20.17 | 1.51% | $26.83 | $1.33 |
| Dec 2025 | 19.87 | 52.85% | $30.8 | $1.55 |
| Sep 2025 | 13 | 26.46% | $30.67 | $2.36 |
| Jun 2025 | 10.28 | -6.55% | $20.66 | $2.01 |
| Mar 2025 | 11 | -6.7% | $19.58 | $1.78 |
| Dec 2024 | 11.79 | -47.3% | $20.87 | $1.77 |
| Sep 2024 | 22.37 | 11.29% | $24.38 | $1.09 |
| Jun 2024 | 20.1 | -18.03% | $25.13 | $1.25 |
| Mar 2024 | 24.52 | -25.29% | $29.91 | $1.22 |
| Dec 2023 | 32.82 | -19.04% | $31.84 | $0.97 |
| Sep 2023 | 40.54 | 4.51% | $35.27 | $0.87 |
| Jun 2023 | 38.79 | 11.98% | $38.01 | $0.98 |
| Mar 2023 | 34.64 | -6% | $37.76 | $1.09 |
| Dec 2022 | 36.85 | 37.6% | $42.38 | $1.15 |
| Sep 2022 | 26.78 | -30.77% | $32.13 | $1.2 |
GMAB Price vs fair value
GMAB average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
GMAB's current PE ratio is lower than its 3, 5 and 10-year averages.
PE comparison
Genmab's price to earnings (P/E) of 18.91 is higher than the industry average but lower than the Healthcare sector and its peers average. In comparison with the Healthcare sector average of 23.87, Genmab's price to earnings (P/E) is 21% lower.
GMAB PE vs peers
In comparison to its peers AMGN and VRTX, GMAB's PE ratio is lower, but it is higher than GILD's and REGN's. Genmab is currently trading at a lower PE ratio (18.91) than its peers average of 26.74.
| Stock name | PE ratio | Market cap |
|---|---|---|
| INCY Incyte Corp | 13.81 | $20.11B |
| REGN Regeneron Pharmaceuticals Inc | 14.36 | $64.09B |
| GILD Gilead Sciences Inc | 17.26 | $159.05B |
| GMAB Genmab | 18.65 | $15.93B |
| BIIB Biogen Inc | 20.6 | $28.44B |
| AMGN Amgen Inc | 23.88 | $186.59B |
| VRTX Vertex Pharmaceuticals Inc | 26.04 | $112.43B |
| ALNY Alnylam Pharmaceuticals Inc | 67.01 | $39.01B |
| MRNA Moderna Inc | N/A | $18.89B |
Frequently asked questions
What is Genmab's PE ratio?
GMAB stock has a price to earnings ratio of 18.91 as of Jun 5, 2026.
What is the 3-year average PE ratio for Genmab (GMAB)?
The average PE ratio for GMAB stock over the past 3 years is 22.1.
What is the 5-year average PE ratio for Genmab (GMAB)?
The average PE ratio for GMAB stock over the past 5 years is 34.17.
What is the highest PE ratio for GMAB?
Over the last nine years, the quarterly PE ratio reached its highest level at 75.61 in the Jun 2021 quarter.
How does the current PE ratio for GMAB compare to its historical average?
GMAB's price to earnings ratio is currently 51% below its 9-year historical average.
How is GMAB's PE ratio calculated (Genmab PE ratio formula)?
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Jun 5, 2026), Genmab's share price is $25.15. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $1.33. Therefore, Genmab's PE ratio for today is 18.91. PE RATIO(18.91) = STOCK PRICE($25.15) / TTM EPS($1.33)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.